# OnCo record paper-felip-impower010-adjuvant-atezolizumab-lancet-2021 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-felip-impower010-adjuvant-atezolizumab-lancet-2021/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-felip-impower010-adjuvant-atezolizumab-lancet-2021" ;
  schema:name "Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010)"@en ;
  schema:description "The first trial to show that immunotherapy after lung cancer surgery delays recurrence. The benefit was concentrated in patients whose tumours expressed PD-L1."@en ;
  schema:url <https://onco.cc/key-papers/paper-felip-impower010-adjuvant-atezolizumab-lancet-2021/> ;
  schema:dateModified "2026-09-25"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/S0140-6736(21)02098-5>, <https://pubmed.ncbi.nlm.nih.gov/34555333/>, <https://clinicaltrials.gov/study/NCT02486718> ;
  onco:tag "lung-evidence" ;
  schema:sameAs <https://doi.org/10.1016/S0140-6736(21)02098-5> ;
  schema:datePublished "2021"^^xsd:gYear ;
  schema:author "Felip E, Altorki N, Zhou C, et al." ;
  onco:related <https://onco.cc/key-papers/paper-lace-adjuvant-cisplatin-pooled-analysis-jco-2008/>, <https://onco.cc/key-papers/paper-checkmate-816-nejm-2022/>, <https://onco.cc/key-papers/paper-heymach-aegean-perioperative-durvalumab-nejm-2023/>, <https://onco.cc/key-papers/paper-keynote-671-n-engl-j-med-2023/> ;
  onco:cancers <https://onco.cc/cancers/lung-cancer/>, <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/resectable-nsclc/>, <https://onco.cc/cancers/pdl1-high-nsclc/> ;
  onco:sections <https://onco.cc/fronts/immunotherapy/>, <https://onco.cc/fronts/surgery/> ;
  onco:technologies <https://onco.cc/terms/ihc/>, <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:targets <https://onco.cc/targets/pd1/> ;
  onco:drugs <https://onco.cc/drugs/atezolizumab/>, <https://onco.cc/drugs/cisplatin/>, <https://onco.cc/drugs/carboplatin/> ;
  onco:companies <https://onco.cc/companies/roche-genentech/> ;
  onco:pathways <https://onco.cc/terms/immune-checkpoint/> ;
  onco:terms <https://onco.cc/terms/neoadjuvant-adjuvant/>, <https://onco.cc/targets/pdl1/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-dormancy-mrd/>, <https://onco.cc/bottlenecks/b-immunotherapy-response/>, <https://onco.cc/bottlenecks/b-biomarker-validation/> ;
  onco:journals <https://onco.cc/journals/lancet/> .